Thai Professor Urges Greater, Not Less, Use Of Tamiflu For Bird Flu
This article was originally published in PharmAsia News
A Thailand professor suggests healthcare providers prescribe a higher dose of Roche's Tamiflu (oseltamivir) for resistant strains of the H5N1 avian influenza virus, not avoid its use altogether. Nicholas White of Mahidol University wrote in a medical journal that despite the threat of resistance, higher doses of the drug should be used because of its fatality rate - 262 deaths out of 433 people infected since 2003. He said common sense argues for higher doses to reduce the fatality of infections. White's article drew criticism from other medical experts who said it was dangerous to rely on a single flu drug such as Tamiflu. (Click here for more
You may also be interested in...
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.
FDA's recommendation that COVID-19 vaccine sponsors conduct two months of median follow-up to support an emergency use authorization may not be long enough, some experts say in what can be viewed as validation for agency's position in battle with White House.